Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
CAS:1051375-16-6
Molecular Formula:C20H19F2N3O5
Alias
More Information
(4R,12As)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12A-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-B][1,3]Oxazine-9-Carboxamide; S/Gsk1349572; Gsk 1349572; Tivicay; Dtg; Dolutegravir Api; Dolutegravir (Gsk1349572); 2H-Pyrido[1',2'
Brief Introduction
Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just "572" the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process. On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada. On January 16, 2014, Tivicay was approved by the European Commission for use throughout the European Union.
CNY 22 Million
49950m²
100-500 People
CRO
CRO
| Product Photo | Specification | Grade | Max Capacity | Certificates | Package | |
|---|---|---|---|---|---|---|
|
||||||
| Pharm Grade | - | - |
25kg /
Fibre Drum
|
Main products:
Dolutegravir
/Sodium 4-Aminosalicylate Dihydrate
/Metoclopramide Hydrochloride
/Ambroxol Hydrochloride
/Ethacridine Lactate Monohydrate
/Metoclopramide
/Metaraminol Bitartrate
/Moxifloxacin Hydrochloride
/Sacubitril
/2-Chloro-4-Nitrobenzoic Acid
/Bictegravir
/Methyl 4-Acetamido-2-Methoxybenzoate
/Methyl 4-Acetamido-5-Chloro-2-Methoxybenzoate
/Bromhexine Hydrochloride
/4-Aminosalicylic Acid
CAS:1092939-17-7
Molecular Formula:C17H21N6O4P
Alias
More Information
3R)-Cyclopentyl-3-[4-(7H-Pyrrolo[2,3-d]Pyrimidin-4-yl)Pyrazol-1-yl]Propionitrile Phosphate; (R)-3-(4-(7H-Pyrrolo[2,3-d]Pyrimidin-4-yl)-1H-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile Phosphate; Jakafi; Jakavi
Brief Introduction
Ruxolitinib phosphate is a potent JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM, respectively, showing 130-fold selectivity over JAK3.
CNY 39.8 Million
19980m²
100-500 People
CRO
CRO
| Product Photo | Specification | Grade | Max Capacity | Certificates | Package | |
|---|---|---|---|---|---|---|
|
||||||
| Pharm Grade | - | - |
25kg /
Fibre Drum
|
Main products:
Ruxolitinib Phosphate
/Relugolix
/Carfilzomib
/Ixazomib Citrate
/Apalutamide
/Avatrombopag
/Fulvestrant
/Lenvatinib Mesylate
/Roxadustat
/Brivaracetam
CAS:109581-93-3
Molecular Formula:C44H71NO13
Alias
More Information
Tacrolimus; Tacrolimus Hydrate; Prograf; Protopic; Tsukubaenolide Hydrate
Brief Introduction
Tacrolimus monohydrate (FK506 monohydrate) is a macrolide compound that binds to the FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, thereby inhibiting T lymphocyte signal transduction and IL-2 transcription. Has strong immunosuppressive properties.
USD 5 Million
50-100 People
Manufacturing
Manufacturing
| Product Photo | Specification | Grade | Max Capacity | Certificates | Package | |
|---|---|---|---|---|---|---|
|
||||||
| Pharm Grade | 180 tons/year |
1kg /
Fibre Drum
|
||||
| Pharm Grade | 180 tons/year |
1kg /
Fibre Drum
|
Main products:
Tacrolimus Monohydrate
CAS:118288-08-7
Molecular Formula:C22H29N3O4S
Alias
More Information
(Z)-Inyl)Oxy)-2-Butenyl); Lafutidine(Subjecttopatentfree); Protecadin; Enyl)Acetamide; Rac-2-(Furfurylsulfinyl)-N-[(Z)-4-{[4-(Piperidinomethyl)-2-Pyridyl]Oxy}But-2-Enyl]Acetamide; (+/-)-2-(Furfurylsulfinyl)-N-[4-[4-(Piperidinomethyl)-2-Pyridyl]Oxy-(Z)-2-Butenyl]Acetamide; N-(4-(4-Piperidinylmethyl)Pyridyl-2-Oxy)Butenyl-2-(Furfurylsulfinyl)Acetamide; 2-((Furan-2-Ylmethyl)Sulfinyl)-N-(4-((4-(Piperidin-1-Ylmethyl)Pyridin-2-Yl)Oxy)But-2-En-1-Yl)Acetamide; (Z)-2-((Furan-2-Ylmethyl)Sulfinyl)-N-(4-((3-(Piperidin-1-Ylmethyl)Pyridin-2-Yl)Oxy)But-2-En-1-Yl)Acetamide; Adefovir Dipivioxil; (Z)-2-((Furan-2-Ylmethyl)Sulfinyl)-N-(4-((3-(Piperidin-1-Ylmethyl)Pyridin-2-Yl)Oxy)But-2-En-1-Yl);
Brief Introduction
Lafutidine, is a special histamine H2 receptor antagonist with acid inhibition and gastrointestinal mucosal protection. The drug inhibits gastric acid secretion by antagonizing histamine H2 receptor. The blocking ability of histamine H2 receptor is 2-85 times that of traditional histamine H2 receptor antagonists. The acid inhibition effect is strong and lasting, and can continuously inhibit the basic secretion of gastric acid, pepsin, nocturnal secretion, tetrapeptide gastrin, uracholine Gastric acid secretion caused by stimulating factors such as gastric dilation.
CNY 90 Million
399600m²
1000+ People
Manufacturer
Manufacturing
| Product Photo | Specification | Grade | Max Capacity | Certificates | Package | |
|---|---|---|---|---|---|---|
|
||||||
| Pharm Grade | - | - |
0.5kg /
BOTTLE
|
Main products:
Lafutidine
/Hydroxyethyl Starch
/Metadoxine
/Tropisetron Hydrochloride
/α-Lipoic Acid
/L-Carnitine
CAS:120685-11-2
Molecular Formula:C35H30N4O4
Alias
More Information
4'-N-Benzoylstaurosporine; Pkc 412,[9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-Methoxy-9-Methyl-1-Oxo-9,13-Epoxy-1H,9H-Diindolo[1,2,3-Gh:3',2',1'-Lm]Pyrrolo[3,4-J][1,7]Benzodiazonin-11-Yl)-N-Methylbenzamide; Cgp 41 251; 4'-N-Benzoyl Staurosprine; Benzoylstaurosporine
Brief Introduction
Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).
After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine. In another trial, the substance has proven ineffective in metastatic melanoma.
CNY 34.6 Million
19980m²
100-500 People
Manufacturing
Manufacturing
| Product Photo | Specification | Grade | Max Capacity | Certificates | Package | |
|---|---|---|---|---|---|---|
|
||||||
| Pharm Grade | - | - |
25kg /
Fibre Drum
|
Main products:
Midostaurin
/Vinorelbine L-Tartrate
/Vincristine Sulfate
/Vincaleukoblastine Sulfate
/Mitomycin C
/Bortezomib
/Epothilone B
/Ixabepilone
/Staurosporine
/Melphalan Hydrochloride
/Lufenuron
/Nitenpyram
/Doramectin
/Milbemite
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!